HCV相关肝硬化患者肝移植术后的抗病毒与免疫调节治疗

焦健; 王江滨

doi:10.3969/j.issn.1001-5256.2014.01.005

HCV相关肝硬化患者肝移植术后的抗病毒与免疫调节治疗

DOI: 10.3969/j.issn.1001-5256.2014.01.005

焦健,
王江滨

吉林大学中日联谊医院消化内科

详细信息

中图分类号: R657.3
计量
- 文章访问数: 155
- HTML全文浏览量: 12
- PDF下载量: 84
- 被引次数: 0
出版历程
- 收稿日期: 2013-11-18
- 出版日期: 2014-01-20

Features of HCV recurrence in patients with HCV- related cirrhosis after liver transplantation and its antiviral and immunomodulatory therapies

Department of Gastroenterology, China Japan Union Hospital, Jilin University

摘要

摘要: HCV相关肝硬化发生肝功能失代偿后的最佳选择可能是肝移植。移植后免疫调节药物尤其是免疫抑制剂的应用可能是加速HCV复发的一个主要因素,如何在减轻移植排斥反应的同时兼顾HCV感染的控制是目前须要探讨的问题。总结了目前HCV相关肝移植术后的抗病毒及免疫调节治疗情况,分析表明,在HCV相关肝硬化肝移植术后进行合理的免疫抑制和抗病毒治疗对于预防HCV复发、延长移植物生存期、改善患者预后具有至关重要的作用,突然改变免疫抑制方案,如快速撤药或改变免疫抑制剂的剂量或类型都有可能导致HCV的复发,类固醇激素缓慢进行性减量和硫唑嘌呤维持治疗也许有益。
- 肝炎病毒属 /
- 肝硬化 /
- 肝移植 /
- 肝炎,丙型,慢性 /
- 免疫抑制剂
Abstract: The best choice of treatment for patients with HCV- related cirrhosis may be liver transplantation once liver decompensation occurs. Immunoregulatory drugs, especially immunosuppressants, may be a main causative factor for accelerated HCV recurrence after liver transplantation. How to control HCV infection while reducing graft rejection is a meaningful problem that needs to be solved. The current antiviral and immunomodulatory therapies after HCV- related liver transplantation are summarized. Analysis showed that proper immunosuppression and antiviral therapy in patients with HCV- related cirrhosis after liver transplantation are of great significance for preventing HCV recurrence, prolonging graft survival, and improving prognosis. Sudden change in immunosuppressive therapy, such as rapid withdrawal or changing the dose or type of immunosuppressant, may lead to HCV recurrence. Slow progressive reduction in steroid hormone and maintenance treatment with azathioprine may be beneficial.
- hepatitis viruses /
- liver cirrhosis /
- liver transplantation /
- hepatitis C, chronic /
- immunosuppressive agents

HTML全文

参考文献(32)

[1]Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association.Recommendation on antiviral therapy to hepatitis B/C virus related hepatocellular carcinoma[J].J Clin Hepatol, 2013, 29 (1) :5-9. (in Chinese) 中华医学会肝病学分会肝癌学组.HBV/HCV相关性肝细胞癌抗病毒治疗专家建议[J].临床肝胆病杂志, 2013, 29 (1) :5-9.

[2]COILLY A, ROCHE B, SAMUEL D.Current management and perspectives for HCV recurrence after liver transplantation[J].Liver Int, 2013, 33 (Suppl 1) :56-62.

[3] RODRIGUEZ-LUNA H, DOUGLAS DD.Natural history of hepatitis C following liver transplantation[J].Curr Opin Infect Dis, 2004, 17 (4) :363-371.

[4]SAMUEL D, FORNS X, BERENGUER M, et al.Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006) [J].J Hepatol, 2006, 45 (1) :127-143.

[5]WIESNER RH, SORRELL M, VILLAMIL F, et al.Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C[J].Liver Transpl, 2003, 9 (11) :s1-s9.

[6]BERENGUER M, AGUILERA V, PRIETO M, et al.Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression[J].J Hepatol, 2006, 44 (4) :717-722.

[7]VIVARELLI M, BURRA P, LA BARBA G, et al.Influence of steroids on HCV recurrence after liver transplantation:A prospective study[J].J Hepatol, 2007, 47 (6) :793-798.

[8]FILIPPONI F, CALLEA F, SALIZZONI M, et al.Double-blind comparison of hepatitis C histological recurrence Rate in HCV+liver transplant recipients given basiliximab+steroids or basiliximab+placebo, in addition to cyclosporine and azathioprine[J].Transplantation, 2004, 78 (10) :1488-1495.

[9]SEGEV DL, SOZIO SM, SHIN EJ, et al.Steroid avoidance in liver transplantation:meta-analysis and meta-regression of randomized trials[J].Liver Transpl, 2008, 14 (4) :512-525.

[10] FIRPI RJ, ZHU H, MORELLI G, et al.Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation[J].Liver Transpl, 2006, 12 (1) :51-57.

[11]INOUE K, SEKIYAMA K, YAMADA M, et al.Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C:controlled trial[J].J Gastroenterol, 2003, 38 (6) :567-572.

[12] BERENGUER M, ROYUELA A, ZAMORA J.Immunosuppression withcalcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation:results of a meta-analysis[J].Liver Transpl, 2007, 13 (1) :21-29.

[13]STRAUSS G, HANSEN BA, KNUDSEN GM, et al.Hyperventilation restores cerebral blood fl ow autoregulation in patients with acute liver failure[J].J Hepatol, 1998, 28 (2) :199-203.

[14] BERENGUER M, ROYUELA A, ZAMORA J.Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation:results of a meta-analysis[J].Liver Transpl, 2007, 13 (1) :21-29.

[15]SHENOY S, HARDINGER KL, CRIPPIN J, et al.A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients[J].Liver Transpl, 2008, 14 (2) :173-180.

[16] SAMONAKIS DN, TRIANTOS CK, THALHEIMER U, et al.Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation[J].Liver Transpl, 2005, 11 (4) :386-395.

[17]BERENGUER M, PRIETO M, SAN JF, et al.Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients[J].Hepatology, 2002, 36 (1) :202-210.

[18]BAIOCCHI L, ANGELICO M, PETROLATI A, et al.Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease[J].Am J Transplant, 2008, 8 (3) :673-678.

[19]EID AJ, BROWN RA, PAYA CV, et al.Associationbetween toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus[J].Transplantation, 2007, 84 (4) :511-516.

[20]WALTER T, DUMORTIER J, GUILLAUD O, et al.Rejection under alpha interferon therapy in liver transplant recipients[J].Am J Transplant, 2007, 7 (1) :177-184.

[21]BYTZER P, TALLEY NJ, JONES MP, et al.Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus[J].Aliment Pharmacol Ther, 2001, 15 (1) :137-142.

[22]WIESNER R, RABKIN J, KLINTMALM G, et al.A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients[J].Liver Transpl, 2001, 7 (5) :442-450.

[23]KORNBERG A, KUPPER B, TANNAPFEL A, et al.Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation[J].Int Immunopharmacol, 2005, 5 (1) :107-115.

[24]de RUVO N, CUCCHETTI A, LAURO A, et al.Preliminary results of a“prope”tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation[J].Transplantation, 2005, 80 (1) :8-12.

[25]KAMAR N, BORDE JS, SANDRES-SAUNE K, et al.Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C[J].Clin Transplant, 2005, 19 (1) :83-89.

[26]RAMIREZ CB, DORIA C, di FRANCESCO F, et al.Basiliximab induction in adult liver transplant recipients with 93%rejectionfree patient and graft survival at 24 months[J].Transplant Proc, 2006, 38 (10) :3633-3635.

[27]CARBONE M, LENCI I, BAIOCCHI L.Prevention of hepatitis C recurrence after liver transplantation:An update[J].World J Gastrointest Pharmacol Ther, 2012, 3 (4) :36-48.

[28]EVERSON GT, TERRAULT NA, LOK AS, et al.The Adult-to-Adult Living Donor Liver Transplantation Cohort Study.A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation[J].Hepatology, 2012, 57 (5) :1752-1762.

[29]BECKEBAUM S, KABAR I, CICINNATI VR.Hepatitis B and C in liver transplantation:new strategies to combat the enemies[J].Rev Med Virol, 2013, 23 (3) :172-193.

[30]MUTIMER D.Understanding the switchbacks:the impact of direct antivirals on the minimization of hepatitis C virus recurrence after transplantation[J].Liver Transpl, 2012, 18 (Suppl 2) :s47-s51.

[31]RABIE R, MUMTAZ K, RENNER EL.Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus:a systematic review and meta-analysis[J].Liver Transpl, 2013, 19 (1) :36-48.

[32] FONTANA RJ, HUGHES EA, APPELMAN H, et al.Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation[J].Liver Transpl, 2012, 18 (9) :1053-1059.

施引文献

资源附件(0)

访问统计